Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 9/20 | 0.55 |
| ▸ | NPC1 | O15118 | 6/20 | 0.52 |
| ▸ | RAB9A | P51151 | 6/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.50 |
| ▸ | STAT1 | P42224 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15887357 | 0.87 | LCK (0.56) | LCKNPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL4128434 | 0.87 | LCK (0.56) | LCKNPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL4294190 | 0.86 | RAB9A (0.66) | NPC1RAB9ASMN1; SMN2ALDH1A1PTPN1 | |
| SCHEMBL4148882 | 0.80 | ALDH1A1 (0.60) | NPC1RAB9ASMN1; SMN2ALDH1A1PTPN1 | |
| SCHEMBL17090573 | 0.80 | LCK (0.69) | LCKNPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL29506738 | 0.80 | LCK (0.69) | LCKNPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL4140464 | 0.79 | LCK (0.49) | LCK | |
| SCHEMBL8977464 | 0.79 | LCK (0.54) | LCKNPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL13799596 | 0.78 | SMN1; SMN2 (0.49) | NPC1RAB9ASMN1; SMN2ALDH1A1PTPN1 | |
| SCHEMBL2666847 | 0.77 | DYRK1A (0.67) | LCKRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8785474-B2 | Vanilloid receptor ligands, pharmaceutical compositions containing them, process for making them, and use thereof to treat pain and other conditions | GRUENENTHAL GMBH (DE) | 2014-07-22 | — | — | US | disclosed |
| US-8785474-B2 | Vanilloid receptor ligands, pharmaceutical compositions containing them, process for making them, and use thereof to treat pain and other conditions | GRUENENTHAL GMBH (DE) | 2014-07-22 | — | — | US | disclosed |
| US-8084484-B2 | Vanilloid receptor ligands, pharmaceutical compositions containing them, process for making them, and use thereof for treating pain and other conditions | GRUENENTHAL GMBH (DE) | 2011-12-27 | — | — | US | disclosed |
| US-8084484-B2 | Vanilloid receptor ligands, pharmaceutical compositions containing them, process for making them, and use thereof for treating pain and other conditions | GRUENENTHAL GMBH (DE) | 2011-12-27 | — | — | US | disclosed |
| US-20110301156-A1 | Vanilloid Receptor Ligands, Pharmaceutical Compositions Containing Them, Process For Making Them, and Use Thereof to Treat Pain and Other Conditions | GRUENENTHAL GMBH (DE) | 2011-12-08 | — | — | US | disclosed |
| US-20110301156-A1 | Vanilloid Receptor Ligands, Pharmaceutical Compositions Containing Them, Process For Making Them, and Use Thereof to Treat Pain and Other Conditions | GRUENENTHAL GMBH (DE) | 2011-12-08 | — | — | US | disclosed |
| CN-101679370-A | Novel vanilloid receptor ligands and the use thereof for the production of pharmaceuticals | GRUENENTHAL GMBH | 2010-03-24 | — | — | CN | disclosed |
| EP-2137178-A2 | NOVEL VANILLOID RECEPTOR LIGANDS AND THE USE THEREOF FOR THE PRODUCTION OF PHARMACEUTICALS | Grünenthal GmbH (DE) | 2009-12-30 | — | — | EP | disclosed |
| US-20090156590-A1 | Vanilloid Receptor Ligands, Pharmaceutical Compositions Containing Them, Process for Making Them, and Use Thereof for Treating Pain and Other Conditions | GRUENENTHAL GMBH (DE) | 2009-06-18 | — | — | US | disclosed |
| WO-2008125342-A2 | NOVEL VANILLOID RECEPTOR LIGANDS AND THE USE THEREOF FOR THE PRODUCTION OF PHARMACEUTICALS | Grünenthal GmbH (DE) | 2008-10-23 | — | — | WO | disclosed |
| WO-2008125342-A2 | NOVEL VANILLOID RECEPTOR LIGANDS AND THE USE THEREOF FOR THE PRODUCTION OF PHARMACEUTICALS | Grünenthal GmbH (DE) | 2008-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156590-A1 | Vanilloid Receptor Ligands, Pharmaceutical Compositions Containing Them, Process for Making Them, and Use Thereof for Treating Pain and Other Conditions | TRPV1, OPRL1, TRPV2 | LCK 589/4885NPC1 693/4885RAB9A 2031/4885 |
| US-20110301156-A1 | Vanilloid Receptor Ligands, Pharmaceutical Compositions Containing Them, Process For Making Them, and Use Thereof to Treat Pain and Other Conditions | TRPV1, OPRL1, TRPV2 | LCK 582/4885NPC1 676/4885RAB9A 1967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.